EUVIMEDEUVIMED entdecken
Crossref

Maraviroc ameliorates doxorubicin-induced atrioventricular block through blocking CCL5-CCR5 interaction in macrophage-cardiomyocyte axis

Heng Wang, Yu Zhang, Li Shen, Gangning Wu, Heng Yu, Luzheng Zhang, Yujin Sun, Song Xue

European Journal of Pharmacology · 2026-06 · 1028 · 178985

DOI: 10.1016/j.ejphar.2026.178985 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmacology, 2026-06. Verfasst von Heng Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China. Electronic address:…. Hauptthemen laut MEDLINE: Doxorubicin, Chemokine CCL5, Macrophages, Maraviroc. Die Arbeit nennt 66 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Doxorubicin (Dox)-induced cardiotoxicity (DIC) remains a challenge in tumor chemotherapy. Targeting macrophage-secreted molecules is a potential strategy to mitigate DIC. Transcriptome analysis of RAW264.7 cells treated with 100 nM Dox revealed increases in 33 proteins located in the extracellular space, including CCL5. An animal model of DIC characterized by degree I atrioventricular block was established in 9-12 weeks old male C57BL/6 mice through three doses of 5 mg/kg Dox intraperitoneally (i.p.) administered every third day. The plasma CCL5 level in these mice consistently increased, which could be attenuated by macrophage depletion using clodronate liposome (15 mg/kg, i. p.). In pharmacological experiments with these animals, administration of maraviroc (MVC) (50 mg/kg, i. p., daily) prevented PR interval elongation caused by Dox. Both in vitro and in vivo experiments showed that MVC attenuated Ca2+ overload induced by CCL5 in H9C2 cells and by Dox in cardiomyocytes from DIC models. Further in vitro experiments confirmed that CCL5 decreases the SERCA2a level and PKA-C, PLB phosphorylation in H9C2 cells, exacerbating Ca2+ overload and CaMKII phosphorylation, which can be attenuated by MVC administration. In conclusion, Dox can induce an increase in macrophage-derived CCL5 in plasma, and MVC targeting the CCL5's receptor CCR5 can ameliorate atrioventricular block caused by Dox toxicity, suggesting that it may be a candidate for DIC treatment in chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinChemokine CCL5MacrophagesMaravirocReceptors, CCR5Myocytes, CardiacCCR5 Receptor AntagonistsAnimalsMaleMiceMice, Inbred C57BLCardiotoxicityRAW 264.7 Cells

Stichwörter der Autor:innen

Atrioventricular blockCCL5CCR5DoxorubicinMacrophagesMaraviroc

Substanzen

DoxorubicinChemokine CCL5MaravirocReceptors, CCR5CCR5 protein, mouseCCR5 Receptor AntagonistsCcl5 protein, mouse

Autor:innen und Institutionen

  • Department of Cardiovascular Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China. Electronic address: nbwh113@sjtu.edu.cn.
  • Department of Cardiovascular Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
  • Department of Biochemistry and Molecular Cell Biology, College of Basic Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
  • Department of Laboratory Medicine, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
  • Department of Cardiovascular Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China. Electronic address: xuesong64@163.com.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, H., Zhang, Y., Shen, L., Wu, G., Yu, H., Zhang, L., Sun, Y., & Xue, S. (2026). Maraviroc ameliorates doxorubicin-induced atrioventricular block through blocking CCL5-CCR5 interaction in macrophage-cardiomyocyte axis. European Journal of Pharmacology, 1028, 178985. https://doi.org/10.1016/j.ejphar.2026.178985

Vancouver

Wang H, Zhang Y, Shen L, Wu G, Yu H, Zhang L, et al. Maraviroc ameliorates doxorubicin-induced atrioventricular block through blocking CCL5-CCR5 interaction in macrophage-cardiomyocyte axis. European Journal of Pharmacology. 2026;1028:178985. doi:10.1016/j.ejphar.2026.178985

BibTeX
@article{Wang2026,
  author = {Wang, Heng and Zhang, Yu and Shen, Li and Wu, Gangning and Yu, Heng and Zhang, Luzheng and Sun, Yujin and Xue, Song},
  title = {Maraviroc ameliorates doxorubicin-induced atrioventricular block through blocking CCL5-CCR5 interaction in macrophage-cardiomyocyte axis},
  journal = {European Journal of Pharmacology},
  year = {2026},
  volume = {1028},
  pages = {178985},
  doi = {10.1016/j.ejphar.2026.178985}
}
Kostenlos starten →